


GSK delivers strong Q3 2022 sales of £7.8 billion +9% CER



Specialty Medicines

£2.7bn +24%
+11% excluding Covid solutions

Vaccines

£2.5bn +5%
+9% excluding Covid solutions

General Medicines

£2.6bn +1%

Total EPS*

255.9p
+>100%

Adjusted EPS

46.9p +11%

Dividend

13.75p

“GSK has delivered another quarter of excellent performance, with strong growth in Specialty Medicines, record sales for our shingles vaccine, and further improvements in operating profit. We are again raising our full year guidance and expect good momentum in 2023, further strengthening our confidence in our performance outlooks, driven by the global expansion of our shingles vaccine and expected new launches including our anticipated RSV vaccine. We are also making good progress to strengthen our early-stage pipeline and will continue to invest in targeted business development to build optionality and support growth in the second half of the decade.”

Emma Walmsley
CEO, GSK

Journalists/media see press release on www.gsk.com for full details on Q3 2022.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 66 to 68 of the press release.

References to growth are at constant exchange rates (CER) unless stated otherwise.

The amounts presented above for continuing operations and Adjusted results exclude the Consumer Healthcare business discontinued operation.

*Primarily reflecting the gain from discontinued operations arising on the demerger of the Consumer Healthcare business

GSK

Ahead Together